top of page
Pfizer's Paxlovid gets a green signal from US-FDA for COVID-19 treatment.

Content Editor: Dr. Rajat Sharma

June 1, 2023 at 10:31:02 PM

COVID-19 treaatment, New Antiviral, FDA approval

Content Editor: Dr. Rajat Sharma

  • FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults.     

  • On 25 May,  the U.S. Food and Drug Administration approved the oral antiviral Paxlovid.

  • This combination of Nirmatrelvir (300 mg) and ritonavir (100 mg) tablets can be used for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.   

  • Paxlovid is not approved or authorized for  

  1. Pre-exposure or post-exposure prophylaxis for prevention of COVID-19. 

  2. Initiation of treatment in patients requiring hospitalization due to severe or critical  COVID-19.

  3. More than 5 days

bottom of page